Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

NCT05322577 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05322577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Terminated
Start date
May 17, 2022
Completion date
November 21, 2025
Enrollment
72 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction cancer